Arch Therapeutics Inc (OTCBB:ARTH) has announced that the US Patent Office has approved a notice of allowance, regarding a broad composition of matter patent. Although the patent was originally developed by MIT and Versitech Limited, Arch Therapeutics holds the exclusive licensing rights, worldwide. The patent covers a wide range of present and proposed Arch products. The products also contain peptides, which tend to form barrier like structures on tissues, thereby preventing passage of bodily fluids.

The company had recently released promising data from one such product, the AC5 surgical Hemostatic Device. The trial included a 21-day repeat exposure skin test, to determine the irritation effects of the device to human skin. This was also the first safety data for the device, from human testing. The results of the trial showed that the AC5 had no irritation effects, to the human skin.

Terrence Norchi, the CEO of ARTH, stated that the results were an important step in demonstrating the clinical safety of AC5. He further added that the data would add to the profile of AC5 in hemostasis and other applications. Regarding the patent, he stated that it confirms the innovative nature of the self-assembling technology and the company’s commitment in the areas of unmet need. He also revealed that tests from the AC5 have shown that it can stop bleeding, when applied to a wound. The CEO concluded by expressing his eagerness at the results from the first human trial, underway in Europe and by revealing plans to file for a CE Mark this summer.

Arch Therapeutics has also filed several patent applications of its own, but it still holds the licensing rights to this technology as well. This tends to allow the company to manufacture and market medical applications of the technology, worldwide. The patent applications are pending in multiple jurisdictions.

Arch Therapeutics Inc (OTCBB:ARTH) closed trading at a share price of $0.47, after gaining 4.91% and having a trade volume of 3.17 million, at the end of the April 7 session.

Previous articleTapImmune Inc. (OTCMKTS:TPIV) Releases TPIV200 Vaccine for Ovarian and Breast Cancer
Next articleRoche Holding Ltd. (ADR) (OTCMKTS:RHHBY) Reports Increased Diagnositc Sales
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.